University of Leicester researcher in potential medical breakthrough
“This new drug could be a game changer for future treatment of asthma” – Professor Chris Brightling, NIHR Senior Research Fellow at the University of Leicester
The first new asthma pill for nearly 20 years has the power to significantly reduce the severity of the condition, a study led by the University of Leicester has found.
The research was funded by Novartis Pharmaceuticals, National Institute for Health Research (NIHR) and the EU (AirPROM), and is described by the lead researcher as “a game changer for future treatment of asthma.”
Three people die every day because of asthma attacks and research shows that two thirds of asthma deaths are preventable, according to Asthma UK.
Fevipiprant (QAW039) significantly decreased the symptoms of asthma, improved lung function, reduced inflammation and repaired the lining of airways.
The drug is currently being evaluated in late stage clinical trials for efficacy in patients with severe asthma, according to ClinTrials.gov.
A total of 61 people took part in the research. One group was given 225mg of the drug twice a day for 12 weeks and the other participants were assigned to a placebo group. Fevipiprant and the placebo were added to the medications the participants were already taking.
The study was designed primarily to examine the effects on inflammation in the airway by measuring the sputum eosinophil count.
The sputum eosinophil is an inflammation measurement of a white blood cell that increases in asthma and is used to assess the severity of this condition.
People who do not have asthma have a percentage of less than one and those with moderate-to-severe asthma typically have a reading of about five per cent.
The rate in people with moderate-to-severe asthma taking the medication was reduced from an average of 5.4 percent to 1.1 percent over 12 weeks, according to the study published today in the prestigious The Lancet Respiratory Medicine journal.
Professor Christopher Brightling, who is a NIHR Senior Research Fellow and Clinical Professor in Respiratory Medicine at the University of Leicester, led the study at the NIHR Respiratory Biomedical Research Unit, which is based at the Glenfield Hospital in Leicester.
Professor Brightling said: “A unique feature of this study was how it included measurements of symptoms, lung function using breathing tests, sampling of the airway wall and CT scans of the chest to give a complete picture of how the new drug works.
“Most treatments might improve some of these features of disease, but with Fevipiprant improvements were seen with all of the types of tests.
“We already know that using treatments to target eosinophilic airway inflammation can substantially reduce asthma attacks.
“This new treatment, Fevipiprant, could likewise help to stop preventable asthma attacks, reduce hospital admissions and improve day-to-day symptoms- making it a ‘game changer’ for future treatment.”
Gaye Stokes from Grantham in Lincolnshire has had severe asthma for 16 years. She took part in the trial and was part of the Fevipiprant group.
The 54-year-old said: “I knew straight away that I had been given the drug. I felt like a completely different person. I had more get up and go, I was less wheezy and for the first time in years I felt really, really well.
“For me, it felt like a complete wonder drug and I can’t wait for it to be available because I really think it could make a huge difference to me.”
After the 12 week trial and Gaye stopped receiving the drug, she said her health started to “go downhill again very quickly”.
Professor Brightling added that the latest advance underpinned the work of the Leicester Precision Medicine Institute, a Centre of Excellence that coalesces and aligns the research missions of the University of Leicester and the NHS in Leicester.
Future treatment of human disease will increasingly move from a ‘one size fits all’ approach to one of tailoring the treatment to the individual patient.
Asthma is a long-term condition that affects the airways. When a person with asthma comes into contact with something that irritates their sensitive airways it causes the body to react in several ways which can include wheezing, coughing and can make breathing more difficult.
The NIHR Leicester Respiratory Biomedical Research Unit – a partnership between the University of Leicester and Leicester’s Hospitals – focuses on promoting the development of new and effective therapies for the treatment of respiratory diseases including severe asthma and chronic obstructive pulmonary disease (COPD).
The Latest on: Asthma pill
via Google News
The Latest on: Asthma pill
- Arab Health to address the exacerbation of asthma in the MENA region as currently only 30% of people are treated in a controlled environmenton December 15, 2019 at 12:44 am
Poor medication adherence, lifestyle, and air quality are all contributing to the increase of asthma sufferers in the MENA region and the subsequent economic burden on society Globally, over 339 ...
- Asthma Medication Market Study: An Emerging Hint of Opportunityon December 13, 2019 at 5:33 am
Dec 13, 2019 (HTF Market Intelligence via COMTEX) -- Advance Market Analytics released the research report of Global Asthma Medication Market, offers a detailed overview of the factors influencing the ...
- A Runner Suddenly Developed Asthma. It Was Stranger Than It Seemed.on December 12, 2019 at 11:25 am
But now she had severe asthma and was allergic to not one but two painkillers. The doctors in the hospital had no answers and suggested she see an allergist. The patient went to see Dr. Elina Jerschow ...
- Roche's (RHHBY) sBLA for Asthma Drug Xolair Accepted by FDAon December 11, 2019 at 8:54 am
The results showed that Xolair, an injectable biologic medicine designed to target and block IgE, was well tolerated, while safety profile was consistent with that observed in previous studies in ...
- A multinational observational study identifying primary care patients at risk of overestimation of asthma controlon December 5, 2019 at 3:19 am
Significant differences were noted in age, gender, body mass index, education level, medication use, side effects, attitudes to preventer inhaler use, inhaler technique review and respiratory ...
- Lung imaging studies of non-identical twins with asthma deepen understanding of the diseaseon December 4, 2019 at 1:06 pm
These studies deepen our understanding of asthma and also open up opportunities for personalized therapies that can target specific areas of the lungs. In a study published recently in the journal ...
- Lung images of twins with asthma add to understanding of the diseaseon December 4, 2019 at 10:45 am
These studies deepen our understanding of asthma and also open up opportunities for personalized therapies that can target specific areas of the lungs.In a study published recently in the journal ...
- Oklahoma Allergy & Asthma Clinic opens new site in Yukonon December 4, 2019 at 6:53 am
(KFOR) – If you suffer from allergies, you’ve likely turned to over-the-counter medication to help control the symptoms ... who need allergy shots won’t have to travel very far to get the care they ...
- Bidirectional association between asthma and migraines in adults: Two longitudinal follow-up studieson December 4, 2019 at 2:21 am
For the classifications of asthma and migraine, both diseases were diagnosed by physicians twice or more, and medication prescriptions were checked for asthma. Moreover, migraines were classified ...
- Prenatal Asthma Attacks Up Complications for Mom and Babyon December 3, 2019 at 1:42 pm
Pregnant women who have asthma need regular antenatal care to discuss their symptoms and ensure their medication is effective," Vestbo stressed. The study was supported by the Institute for Clinical ...
via Bing News